Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Introduces Updated Designer Drug and Oral Fluid Compendiums

Published: Tuesday, February 12, 2013
Last Updated: Tuesday, February 12, 2013
Bookmark and Share
Webinars to highlight new applications for LC/MS, MS.

Agilent Technologies Inc. has introduced new application compendiums on designer drug testing and toxicology of oral fluids.

Also available is an expanded GC/MS Designer Drug Library. The only resource of its kind, this searchable library includes designer stimulants that are often marketed as "bath salts" as well as additional cannabinoid compounds.

In tandem with the release of these new resources, Agilent is sponsoring monthly webinars featuring industry experts who will discuss new LC/MS and MS applications for forensic detection and analysis of designer drugs and metabolites.

"Designer drugs-especially bath salts-continue to make headlines across the country," said Tom Gluodenis, Agilent's global marketing manager of Forensics and Toxicology.

Gluodenis continued, "The important resources we're introducing today, used in collaboration with our specialized GC/MS laboratory technologies, provide forensic practitioners, crime laboratories, and federal workplace drug-testing programs with cost-effective, end-to-end solutions for designer drug screening and analysis."

Designer drugs are formulated to get around existing definitions of illicit compounds. Once difficult to trace, these substances can now be quickly identified and analyzed using Agilent's GC/MS technologies.

Agilent's expanded application compendium, "Identification of Synthetic Cannabinoids in Herbal Incense Blends by GC/MS," contains information on 45 cannabinoids and describes how to facilitate rapid screening and identification of these marijuana-like compounds. A companion compendium, "Analysis of Designer Stimulants by GC/MS," describes the analysis of 30 stimulants.

Agilent developed these compendiums, and the expanded GC/MS Designer Drug Library, in collaboration with NMS Labs.

Screening oral fluid is an accurate and effective alternative to screening urine or blood. It provides many collection advantages, and samples can be more easily analyzed using highly sensitive enzyme immunoassays and LC-MS/MS instrumentation.

Agilent's updated oral fluid compendium, "Drugs and Metabolites in Oral Fluid: Immunoassay Screening and LC/MS/MS Confirmation and Quantification," is a comprehensive treatise on the detection of drugs of abuse in oral fluid, covering 100 drugs in 11 classes.

The compendium includes information on sample collection and preparation, immunoassay screening and LC/QQQ confirmation. It also reflects changes to the mandatory guidelines for Federal Workplace Drug Testing Programs, and contains protocols for all the newly recommended Schedule II prescription medications. Agilent developed the compendium in collaboration with Immunalysis Corp.

To download the application compendium "Drugs and Metabolites in Oral Fluid," visit Agilent's Forensics & Toxicology website.

Webinar Series for Forensic Practitioners

Throughout the year, Agilent will sponsor a monthly online educational series focusing on the analysis of designer drugs and drugs of abuse. Hosted by RTI International's online education service on www.ForensicEd.org, the webinars listed below will also be available for replay following the live events. Additional webinars will be announced at a later date.

Comprehensive Workflow for Screening and Confirmation of Drugs in Oral Fluids, now accessible for replay at Forensic Science Education: Dr. Christine Moore of Immunalysis Corp. discusses designer drug compendiums, oral fluids sample collection, preparation, drug extraction, immunoassay screening and LC/QQQ confirmation equipment.

LC/QQQ Screening for 300 Designer Drugs and Metabolites, Tuesday, Feb. 26 at 9 a.m. and 1 p.m. EST: Dr. Tony DiCaprio of Florida International University's-, Forensic Science Institute will describe current work focusing on the development of LC-QQQ-MS/MS-based methods for rapid screening of designer drugs in forensic analysis.

GC/MS and GC/QQQ Screening for 300 Designer Drugs and Metabolites, Thursday, April 18 at 9 a.m. and 1 p.m. EST: Dr. Jose Almirall, also of Florida International University's Forensic Science Institute, will focus on the expanded Designer Drug Library that FIU has developed in partnership with Agilent; discussion will also focus on the entire workflow for effective and rapid screening of designer drugs.

Webinar co-sponsor RTI International is the Center of Excellence for the United States National Institute of Justice. The upcoming webinars are part of RTI's specialized forensic education service, which provides online forensic science training and continuing education courses to practitioners in forensic science, law enforcement, medico-legal death investigation and forensic toxicology.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent’s Thought Leader Award Supports Dr. Paul Watkins
Dr. Watkins has received the award in recognition of his ongoing work developing integrated methods to predict DILI.
Thursday, January 23, 2014
Agilent Technologies to Separate into Two Public Companies
Life sciences, diagnostics and applied markets (LDA) that will retain the Agilent name, and the other company will be comprised of Agilent's electronic measurement (EM) products.
Monday, September 23, 2013
Dr. Emmanuel Barillot Receives Agilent Thought Leader Award
Award will support Dr. Barillot’s Web-based tools for cancer and drug-safety research.
Friday, August 30, 2013
Agilent to Sponsor Global Forensics Congress in Portugal
Latest LC, GC, MS and mobile-measurement solutions to be featured at September event.
Tuesday, August 27, 2013
Agilent Supports Russell Thomas’ Research at the Hamner Institutes for Health Sciences
Russell supported for his work developing methods to predict drug-induced liver injury.
Thursday, December 08, 2011
Agilent Technologies’ LC/MS Manufacturing Achieves ISO 13485 Certification
6100 Series single quadrupole and 6400 Series triple quadrupole systems now manufactured under ISO 13485 certification.
Monday, September 12, 2011
Agilent Technologies Collaborates with UC Davis on Breakthrough Food-Safety Research
Technology aims to revolutionize food safety by reducing identification time of food-borne bacteria.
Thursday, December 09, 2010
Agilent and Johns Hopkins to Research Toxicity Pathways for Embryonic Brain Development Using Metabolomics
The work could help identify possible contributions of chemicals to disorders such as autism and attention hyperactivity disorders.
Friday, August 20, 2010
BIOCIUS and Agilent Launch High-throughput, RapidFire® Mass Solution for Drug Discovery
Advanced, integrated system for high quality in vitro ADME analysis unveiled at ASMS Conference, May 23-May 27.
Friday, May 21, 2010
Automatic Productivity for Life Science Discovery
Agilent Automation Solutions has announced a 12-page brochure 'Automatic productivity for life science discovery.'
Friday, March 26, 2010
Agilent and the National Center for Food Safety and Technology Collaborate to Develop Food Testing Methods
The collaboration will develop new scientific methods for food testing to solve problems facing global food supply chains.
Wednesday, March 03, 2010
Phytronix and Agilent to Co-Market Phytronix LDTD Ion Source with Agilent Mass Spectrometers
The non-exclusive co-marketing agreement aims to promote the Phytronix Laser Diode Thermal Desorption Ion Source with Agilent mass spectrometers.
Wednesday, June 10, 2009
Regulators OK Agilent buy of Stratagene
Federal Antitrust Regulators Approve Agilent's Purchase of Stratagene
Monday, May 14, 2007
FDA Selects Agilent’s Dual-Mode Platform for MAQC Project
FDA will use Agilent’s dual-mode platform for pharmacogenomics and toxicogenomics studies.
Friday, January 13, 2006
Scientific News
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Novel Technique for Kidney Research Developed
To better understand how the treatment leads to kidney damage, and possibly prevent it, a team of researchers at Yale School of Medicine developed a new 3D-imaging technique to peer deep into these vital organs.
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
A Better Way to Personalize Bladder Cancer Treatments
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.
Breath of Fresh Air for Asthmatics
Researchers hope to develop a platform that will allow a range of drugs to be delivered by inhalation.
Capturing Cell Growth in 3-D
Spinout’s microfluidics device better models how cancer and other cells interact in the body.
Elastic Patch Releases Drugs in a Stretch
Researchers from have developed a drug delivery technology that consists of an elastic patch that can be applied to the skin and will release drugs whenever the patch is stretched.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Liposomes: A Basis for Drugs of the Future
An international group of scientists have recently presented a review of liposomes, microscopic capsules widely used all over the world in the development of new drugs.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!